An ultra-rare disease affects fewer than 1 in 50,000 people and is among the toughest challenges in medicine, with very limited treatment options. In the U.S., fewer than 7,000 people live with any given ultra-rare condition.
The company we are highlighting today, X4 Pharmaceuticals Inc. (XFOR), developed the first and only FDA-approved therapy for one such ultra-rare disease and is now exploring the drug's potential in additional indications.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.